Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
about
Mind-body movement therapies for Parkinson's diseaseTime to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease.Balance dysfunction in Parkinson's diseaseParkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and DiagnosisAssociation of Parkinson's Disease and Its Subtypes with Agricultural Pesticide Exposures in Men: A Case-Control Study in FranceAn update on the diagnosis and treatment of Parkinson diseaseA cognitive-perceptual approach to conceptualizing speech intelligibility deficits and remediation practice in hypokinetic dysarthriaCurrent clinical practice for Parkinson's disease among Chinese physicians, general neurologists and movement disorders specialists: a national survey.Enhancing Diagnostic Accuracy of aMCI in the Elderly: Combination of Olfactory Test, Pupillary Response Test, BDNF Plasma Level, and APOE GenotypeClinical profile of parkinsonism and Parkinson's disease in Lagos, Southwestern Nigeria.The utility of the combination of a SPECT study with [123I]-FP-CIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes.Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.Clinical profile of Parkinson's disease in the Gumei community of Minhang district, Shanghai.Quality improvement in neurology: AAN Parkinson disease quality measures: report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology.Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.Olfactory function in corticobasal syndrome and frontotemporal dementiaClinical aspects of palliative care in advanced Parkinson's disease.Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease.Unbiased approaches to biomarker discovery in neurodegenerative diseasesDiagnosis and treatment of Parkinson disease: molecules to medicineStructural and functional imaging in parkinsonian syndromes.Weight loss and impact on quality of life in Parkinson's disease.Deep brain stimulation for early-stage Parkinson's disease: an illustrative case.The role of autonomic testing in the differentiation of Parkinson's disease from multiple system atrophy.Side effects induced by the acute levodopa challenge in Parkinson's Disease and atypical parkinsonisms.A new cultural adaptation of the University of Pennsylvania Smell Identification Test.Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease.Did depressive symptoms affect recognition of emotional prosody in Parkinson's disease?Evaluation of Nonmotor Symptoms in Diagnosis of Parkinsonism and Tremor.New chemosensory component in the U.S. National Health and Nutrition Examination Survey (NHANES): first-year results for measured olfactory dysfunction.Cranial nerve I: olfaction.Exercise therapy, quality of life, and activities of daily living in patients with Parkinson disease: a small scale quasi-randomised trial.Diagnostic test systematic reviews: bibliographic search filters ("Clinical Queries") for diagnostic accuracy studies perform well.The search for biomarkers in Parkinson's disease: a critical review.Primary health care providers' knowledge gaps on Parkinson's disease.The cortical signature of symptom laterality in Parkinson's disease.Exploiting the potential of molecular profiling in Parkinson's disease: current practice and future probabilities.Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease.Adjunctive therapy in Parkinson's disease: the role of rasagiline.Combined assessment of midbrain hyperechogenicity, hyposmia and motor asymmetry improves diagnostic accuracy in early Parkinson's disease.
P2860
Q24194581-DC0E83C8-95A2-45E4-94E8-BD94525D0BF5Q27686808-23229FB6-301C-4CEA-9483-DBF531F8DB86Q28081188-FA3107B4-576D-4162-BC9C-3DBA864D0D10Q28384572-7C9FDEC9-11BE-40A3-9C8A-B7313F42A75DQ28392892-5E35FB38-82A3-4130-B093-ACD2F6AA6C42Q30243899-288F62BE-B752-4490-8F9F-14B9FFF0BD6FQ30474147-E1FC5BED-C064-462B-B12A-6AA0F5B53206Q31108322-1E7D813A-6718-4BCB-B5AA-2998D3440DDCQ31154141-81FAA918-A05E-42AF-8637-FDBBDD6F6476Q33522059-5FBDB758-C212-4900-A5C3-219AC495DED1Q33693399-A6294986-5941-47A3-9E92-8BC8381DFC24Q33731897-A162C968-27C0-48D9-AD6B-661B2567689AQ33846298-0690978B-68F6-4233-9221-853409A088B3Q34152355-A0E86C46-9F7F-418D-B5BF-2C482DD762DEQ34301396-BC66CC02-2E50-406D-A9BB-8D20820647D9Q34330732-35BBF78D-35F1-43CB-9A1D-DA48D68963DBQ34457767-4CBE923A-9A56-4878-AD1C-AC0373D1E125Q34550489-0E60F587-0ED1-4AB8-A373-61ABF3A863F4Q34625918-996B47DF-568D-423C-BDE0-7B7F612861A1Q34698876-CC7AE447-5799-4B70-A8B2-B61E03939DAEQ35057021-FF23F12F-E5D2-4BF5-98B6-0D6FDE616CE5Q35566032-3BAF3BEF-0CC0-488B-85D4-F62107A18D09Q35613111-B590232D-1750-474E-9DB2-054388588101Q35923029-C5399CA4-41BD-47A9-9255-FEADC008E3F4Q36282655-B43193AD-A521-4A46-B89F-B9D3CF1889F9Q36554975-B851DFC3-EE75-4393-960D-67798B6AAFD0Q36847246-6036A609-DD52-42C0-BE7C-D89F5D4510A4Q36853959-D560B1DF-AA74-46CA-B40B-BE7E9F74722BQ37043936-5636CADB-4296-47B7-8A3E-E0AF54E13FC7Q37276911-EABACF94-E9C6-4CFC-B62C-0E42D84E592BQ37323532-1808BB3F-E6F8-4F5D-A1AE-039B3291A4B6Q37329085-C042EE68-95BE-43AF-A9C4-718A9BCFD056Q37332791-482E4A4E-E09F-42BC-8CD2-DA34972CDDA2Q37352054-62AF2E74-7276-4FAC-9A4D-A8D20EC31208Q37607924-F2A798E7-B6BE-401A-998F-140F13211B91Q37660839-62FB96C0-9160-45BA-B147-05628A5554CBQ37809870-F82CA7F4-10DD-4738-AAC2-792ADC5059DAQ37946305-9593C605-2FE4-499F-9811-CF0B799ADB17Q38026830-07F15CE8-1F1B-4AB4-A692-FE01972401DAQ38045906-313CA37F-9080-433B-9B08-7FCAC66B2361
P2860
Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Practice Parameter: diagnosis ...... American Academy of Neurology.
@ast
Practice Parameter: diagnosis ...... American Academy of Neurology.
@en
type
label
Practice Parameter: diagnosis ...... American Academy of Neurology.
@ast
Practice Parameter: diagnosis ...... American Academy of Neurology.
@en
prefLabel
Practice Parameter: diagnosis ...... American Academy of Neurology.
@ast
Practice Parameter: diagnosis ...... American Academy of Neurology.
@en
P2093
P1433
P1476
Practice Parameter: diagnosis ...... American Academy of Neurology.
@en
P2093
G Gronseth
J Perlmutter
O Suchowersky
Quality Standards Subcommittee of the American Academy of Neurology
T Zesiewicz
W J Weiner
P304
P356
10.1212/01.WNL.0000215437.80053.D0
P407
P577
2006-04-01T00:00:00Z